CNTX vs. ONTX, TLPH, XLO, FBIO, GLTO, MIRA, FLGC, NRBO, ITRM, and NCNA
Should you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Onconova Therapeutics (ONTX), Talphera (TLPH), Xilio Therapeutics (XLO), Fortress Biotech (FBIO), Galecto (GLTO), MIRA Pharmaceuticals (MIRA), Flora Growth (FLGC), NeuroBo Pharmaceuticals (NRBO), Iterum Therapeutics (ITRM), and NuCana (NCNA). These companies are all part of the "pharmaceutical preparations" industry.
Onconova Therapeutics (NASDAQ:ONTX) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
Onconova Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 1,000.00%. Context Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 189.44%. Given Context Therapeutics' higher possible upside, research analysts plainly believe Onconova Therapeutics is more favorable than Context Therapeutics.
Onconova Therapeutics received 372 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 59.97% of users gave Onconova Therapeutics an outperform vote while only 58.82% of users gave Context Therapeutics an outperform vote.
Onconova Therapeutics has higher revenue and earnings than Context Therapeutics. Onconova Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Context Therapeutics had 9 more articles in the media than Onconova Therapeutics. MarketBeat recorded 12 mentions for Context Therapeutics and 3 mentions for Onconova Therapeutics. Context Therapeutics' average media sentiment score of 0.96 beat Onconova Therapeutics' score of 0.07 indicating that Onconova Therapeutics is being referred to more favorably in the media.
8.0% of Onconova Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 3.3% of Onconova Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Context Therapeutics has a net margin of 0.00% compared to Context Therapeutics' net margin of -8,930.97%. Context Therapeutics' return on equity of -95.43% beat Onconova Therapeutics' return on equity.
Onconova Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.
Summary
Onconova Therapeutics beats Context Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Context Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Context Therapeutics Competitors List
Related Companies and Tools